| Citation: |
XU Shuai-shuai, LI Shuo, LI Hao, et al. Expression of monocarboxylate transporter 4 in pancreatic cancer and its prognostic value[J]. Chin J Clin Med, 2020, 27(5): 730-734. DOI: 10.12025/j.issn.1008-6358.2020.20201945
|
To determine the expression of monocarboxylate transporter 4 (MCT4) in pancreatic cancer tissue and its prognostic value after radical resection.
The clinical data of 379 pancreatic cancer patients who underwent radical resection at Pancreatic Surgery of Fudan University Shanghai Cancer Center from February 2010 to June 2014 were retrospectively included in the study. The expression of MCT4 was tested with immunohistochemical staining and its relationship with clinicopathological characteristics of patients was investigated. Kaplan-Meier survival curve and multivariate Cox regression analysis were applied to evaluate the prognostic value of MCT4 expression.
Patients with positive expression of MCT4 protein were prone to have larger tumor size (P=0.004), greater lymph node metastasis (P=0.005), and higher TNM stage (P=0.011). The median overall survival (OS, 12.4 months) time and recurrence-free survival (RFS, 7.3 months) time of patients with positive expression of MCT4 were significantly shorter than those of patients with negative expression of MCT4 (21.3 months, P < 0.001; 11.4 months, P < 0.001). Multivariate Cox regression analysis results showed that the positive expression of MCT4 was an independent predictor of shorter OS (hazard ratio=1.814, 95% confidence interval 1.433-2.296, P < 0.001) and RFS (hazard ratio=1.648, 95% confidence interval 1.319-2.059, P < 0.001) in pancreatic cancer patients after radical resection.
The positive expression of MCT4 is an independent prognostic factor for pancreatic cancer patients after radical resection, and might be a potential marker for the selection and treatment of patients with high recurrence risk.
| [1] |
STROBEL O, NEOPTOLEMOS J, JÄGER D, et al. Optimizing the outcomes of pancreatic cancer surgery[J]. Nat Rev Clin Oncol, 2019, 16(1):11-26. DOI: 10.1038/s41571-018-0112-1
|
| [2] |
VAN ROESSEL S, KASUMOVA G G, VERHEIJ J, et al. International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer[J]. JAMA Surg, 2018, 153(12):e183617. DOI: 10.1001/jamasurg.2018.3617
|
| [3] |
BOSSHART P D, KALBERMATTER D, BONETTI S, et al. Mechanistic basis of L-lactate transport in the SLC16 solute carrier family[J]. Nat Commun, 2019, 10(1):2649. DOI: 10.1038/s41467-019-10566-6
|
| [4] |
PAYEN V L, MINA E, VAN HÉE V F, et al. Monocarboxylate transporters in cancer[J]. Mol Metab, 2020, 33:48-66. DOI: 10.1016/j.molmet.2019.07.006
|
| [5] |
徐华祥, 徐帅帅, 李硕, 等.术前血清CA125预测血清CA19-9正常胰腺癌患者术后生存的价值[J].中国临床医学, 2020, 27(1):50-54. http://www.c-jcm.com/zglcyx/ch/reader/view_abstract.aspx?file_no=20192204&flag=1
|
| [6] |
SUN X Y, WANG M Z, WANG M S, et al. Role of proton-coupled monocarboxylate transporters in cancer:from metabolic crosstalk to therapeutic potential[J]. Front Cell Dev Biol, 2020, 8:651. DOI: 10.3389/fcell.2020.00651
|
| [7] |
SUKEDA A, NAKAMURA Y, NISHIDA Y, et al. Expression of monocarboxylate transporter 1 is associated with better prognosis and reduced nodal metastasis in pancreatic ductal adenocarcinoma[J]. Pancreas, 2019, 48(8):1102-1110. DOI: 10.1097/MPA.0000000000001369
|
| [8] |
MCDONALD P C, CHAFE S C, BROWN W S, et al. Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia[J]. Gastroenterology, 2019, 157(3):823-837. DOI: 10.1053/j.gastro.2019.05.004
|
| [9] |
ZHAO Y B, LI W, LI M H, et al. Targeted inhibition of MCT4 disrupts intracellular pH homeostasis and confers self-regulated apoptosis on hepatocellular carcinoma[J]. Exp Cell Res, 2019, 384(1):111591. DOI: 10.1016/j.yexcr.2019.111591
|
| [10] |
MARTINEZ-OUTSCHOORN U, SOTGIA F, LISANTI M P. Tumor microenvironment and metabolic synergy in breast cancers:critical importance of mitochondrial fuels and function[J]. Semin Oncol, 2014, 41(2):195-216. DOI: 10.1053/j.seminoncol.2014.03.002
|
| [11] |
KUO T C, HUANG K Y, YANG S C, et al. Monocarboxylate transporter 4 is a therapeutic target in non-small cell lung cancer with aerobic glycolysis preference[J]. Mol Ther Oncolytics, 2020, 18:189-201. DOI: 10.1016/j.omto.2020.06.012
|
| [12] |
KONG S C, NØHR-NIELSEN A, ZEEBERG K, et al. Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells[J]. Pancreas, 2016, 45(7):1036-1047. DOI: 10.1097/MPA.0000000000000571
|
DownLoad: